Sign Up to like & get
recommendations!
0
Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.4551
Abstract: 4551 Background: In MIBC pts, especially in those with high risk features including lymphovascular invasion, hydronephrosis, T3b disease, or variant histology, cisplatin-based NAC followed by cystectomy improves overall survival as compared with cystectomy alone. However,…
read more here.
Keywords:
high risk;
durva;
ineligible cisplatin;
cisplatin based ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.8013
Abstract: 8013 Background: For patients (pts) with unresectable locally-advanced NSCLC, standard of care involves durva consolidation after concurrent CRT, although its benefit in ALK+ tumors is unclear. The ALINA trial demonstrated adjuvant efficacy of alectinib in…
read more here.
Keywords:
durva;
alk tki;
consolidation;
alk nsclc ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.4_suppl.684
Abstract: 684 Background: Preliminary results of the interim analysis of the ARCADIA trial have shown that combining multitargeted receptor tyrosine kinase inhibitor CABO with the checkpoint inhibitor DURVA has promising activity and a manageable safety profile…
read more here.
Keywords:
durva;
hla;
analysis;
trial ... See more keywords